Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL897656 | 0.89 | ALK (0.60) | ALKSRPK1 | |
| SCHEMBL898305 | 0.89 | SRPK1 (0.65) | ALKSRPK1 | |
| SCHEMBL897220 | 0.87 | ALK (0.66) | ALKSRPK1 | |
| SCHEMBL897528 | 0.87 | ALK (0.92) | ALKSRPK1 | |
| SCHEMBL7809147 | 0.86 | ALK (0.52) | ALK | |
| SCHEMBL896718 | 0.86 | ALK (0.60) | ALKSRPK1 | |
| SCHEMBL20004666 | 0.85 | ALK (0.60) | ALKSRPK1 | |
| SCHEMBL896685 | 0.85 | ALK (0.76) | ALK | |
| SCHEMBL897435 | 0.85 | ALK (0.65) | ALK | |
| SCHEMBL15061912 | 0.85 | ALK (0.78) | ALKSRPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114327-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-04-10 | — | — | US | disclosed |
| US-20230398096-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230398096-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230142119-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230142119-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-11 | — | — | US | disclosed |
| CN-110891947-B | Process for preparing ailutinib or a pharmaceutically acceptable salt thereof | 北京费森尤斯卡比医药有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-09-29 | — | — | US | disclosed |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-09-29 | — | — | US | disclosed |
| US-20210371410-A1 | PROCESS FOR PREPARING ALECTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2021-12-02 | — | — | US | disclosed |
| US-20210052550-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-02-25 | — | — | US | disclosed |
| US-9126931-B2 | Tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-09-08 | — | — | US | disclosed |
| US-9126931-B2 | Tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-09-08 | — | — | US | disclosed |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2606886-A1 | COMPOSITION CONTAINING TETRACYCLIC COMPOUND | Chugai Seiyaku Kabushiki Kaisha (JP) | 2013-06-26 | — | — | EP | disclosed |
| US-20130143877-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-06-06 | — | — | US | disclosed |
| US-20130143877-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-06-06 | — | — | US | disclosed |
| EP-2441753-A1 | TETRACYCLIC COMPOUND | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-04-18 | — | — | EP | disclosed |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2012-04-05 | — | — | US | disclosed |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143877-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | ALK, ALPI, TTR | ALK 1/4885SRPK1 3494/4885 |
| US-20230142119-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | ALK 1/4885SRPK1 3208/4885 |
| US-20250114327-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | ALK, ALPI, TTR | ALK 1/4885SRPK1 3494/4885 |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | ALK 1/4885SRPK1 3208/4885 |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | ALK 1/4885SRPK1 3208/4885 |
| US-20230398096-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | ALK, ALPI, TTR | ALK 1/4885SRPK1 3494/4885 |
| US-20210371410-A1 | PROCESS FOR PREPARING ALECTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PLEC, SF3B5, FCGR3B | ALK 78/4885SRPK1 1689/4885 |
| US-20210052550-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | ALK, ALPI, TTR | ALK 1/4885SRPK1 3494/4885 |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | ALK 1/4885SRPK1 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.